Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 16/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235971 | 0.88 | CCR8 (0.48) | S1PR5S1PR1S1PR3SIGMAR1ALDH1A1 | |
| SCHEMBL25342485 | 0.88 | S1PR5 (0.49) | S1PR5S1PR1S1PR3SIGMAR1CYP2D6 | |
| SCHEMBL31024716 | 0.88 | S1PR5 (0.49) | S1PR5S1PR1S1PR3SIGMAR1CYP2D6 | |
| SCHEMBL26134138 | 0.83 | S1PR5 (0.47) | S1PR5S1PR1S1PR3SIGMAR1ALDH1A1 | |
| SCHEMBL31380547 | 0.82 | S1PR5 (0.46) | S1PR5S1PR1S1PR3SIGMAR1ALDH1A1 | |
| SCHEMBL31236031 | 0.82 | S1PR5 (0.46) | S1PR5S1PR1S1PR3SIGMAR1ALDH1A1 | |
| SCHEMBL34460295 | 0.82 | S1PR5 (0.46) | S1PR5S1PR1S1PR3SIGMAR1ALDH1A1 | |
| SCHEMBL10265348 | 0.81 | SIGMAR1 (0.61) | S1PR5SIGMAR1CYP2D6ALDH1A1TP53 | |
| SCHEMBL325502 | 0.81 | SIGMAR1 (0.58) | S1PR5S1PR1S1PR3SIGMAR1CYP2D6 | |
| Bromide SCHEMBL325898 | 0.80 | SIGMAR1 (0.60) | S1PR5SIGMAR1CYP2D6ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2025026283-A1 | COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF | 甘李药业股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4471033-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-118632848-A | Cerebellar protein E3 ubiquitin ligase inhibitors | 甘李药业股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2024156294-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | 甘李药业股份有限公司 | 2024-08-02 | — | — | WO | disclosed |
| WO-2023143589-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | S1PR5 4103/4885S1PR1 3780/4885S1PR3 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.